

## InstyMeds Outcomes Study Summary

March 2019

### Study Background

- Study Period: 2013-2018
- Patient Visits: 75,758
- Study Location: Wisconsin ED
- Study Focus: UTI, URI and Pneumonia

### Analysis UTI

- Total UTI Visits: 1,668
- Probability of return visit within 2 weeks, non-InstyMeds: 5.3%
- Probability of return visit within 2 weeks, InstyMeds: 1.3%
- Fisher Exact Test  $P=0.0029$ ; significant at  $P<0.05$

### Analysis Upper Respiratory and Pneumonia

- Total URI and Pneumonia Visits: 3050
- Probability of return visit within 2 weeks, non-InstyMeds: 3.3%
- Probability of return visit within 2 weeks, InstyMeds: 2.0%
- $P>0.05$

### Discussion

Study definitively proves that InstyMeds improves outcomes by increasing the primary medication adherence in Urinary Tract Infection patients. While the Upper Respiratory Infection and Pneumonia comparison did not show statistical significance, it is probable that a larger dataset would lead to such a finding.

Confidential property of InstyMeds. Do not distribute or reproduce without express permission from InstyMeds.